Sherwin Batoon, MD
Geriatric Medicine · Flushing, NYNPI 1609947191
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 573 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$913
- GSK$898
- Abbott$691
- AbbVie$637
- plus $5K from 33 others
What the payments were for
- Food & beverage$11,21599%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 81 | $1,530 |
| Novo Nordisk | 67 | $1,418 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 58 | $913 |
| GSK | 49 | $898 |
| Abbott | 28 | $691 |
| AbbVie(2 entities) | 30 | $637 |
| Amgen(2 entities) | 30 | $487 |
| Johnson & Johnson | 25 | $478 |
| Amarin Pharma, Inc. | 22 | $451 |
| Kowa Pharmaceuticals America, Inc. | 25 | $445 |
| Sanofi-aventis U.S. LLC | 16 | $340 |
| Novartis | 17 | $312 |
| Merck | 14 | $298 |
| Daiichi Sankyo Inc. | 10 | $270 |
| Lilly USA, LLC | 11 | $226 |
| Pfizer | 13 | $204 |
| Phathom Pharmaceuticals, Inc. | 8 | $181 |
| Xeris Pharmaceuticals, Inc. | 9 | $159 |
| Dexcom, Inc. | 2 | $155 |
| Gilead | 7 | $132 |
| Boehringer Ingelheim | 6 | $124 |
| Bayer | 6 | $123 |
| Hikma Pharmaceuticals USA | 6 | $122 |
| ANI Pharmaceuticals, Inc. | 4 | $103 |
| Cumberland Pharmaceuticals, Inc. | 4 | $79 |
| Endo Pharmaceuticals Inc. | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $65 |
| Validus Pharmaceuticals LLC | 3 | $60 |
| Scilex Pharmaceuticals Inc. | 2 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $44 |
| Eyevance Pharmaceuticals LLC | 2 | $40 |
| Neurelis, Inc. | 1 | $31 |
| Vistapharm, Inc. | 2 | $27 |
| Insulet Corporation | 1 | $26 |
| Mylan Specialty L.p. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,275 in reported general payments places this provider in the 95th percentile of 400 geriatric medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 308 | $240,765 |
| JardianceEmpagliflozin | 190 | $176,270 |
| OzempicSemaglutide | 153 | $155,127 |
| JanuviaSitagliptin Phosphate | 184 | $154,143 |
| RybelsusSemaglutide | 100 | $107,952 |
| EliquisApixaban | 71 | $62,573 |
| VascepaIcosapent Ethyl | 78 | $43,047 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $40,826 |
| Metformin Er GastricMetformin Hcl | 20 | $37,237 |
| JanumetSitagliptin Phos/Metformin Hcl | 42 | $35,570 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $34,801 |
| XareltoRivaroxaban | 33 | $30,029 |
| EntrestoSacubitril/Valsartan | 21 | $27,409 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $26,711 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $21,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,530 | $288,067400 claims |
| Novo NordiskOzempic, Rybelsus | $1,418 | $263,079253 claims |
| MerckJanuvia, Janumet | $298 | $189,713226 claims |
| Boehringer IngelheimJardiance | $124 | $176,270190 claims |
| PfizerEliquis | $204 | $62,57371 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $898 | $47,75967 claims |
| Johnson & JohnsonXarelto | $478 | $30,02933 claims |
| NovartisEntresto | $312 | $27,40921 claims |
| AbbVieLinzess, Restasis | $637 | $27,00333 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $445 | $15,58841 claims |
| Lilly USA, LLCMounjaro | $226 | $14,32014 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $913 | $8,21115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 geriatric medicine providers in New York.
Other geriatric medicine in Flushing
- Mallikarjuna ReddyFlushing$5K
- Zheng-Bo HuangFlushing$4K
- Wen DombrowskiBrooklyn$45K
- Sharon BrangmanSyracuse$45K
- Howard FillitNew York$42K
- Adam CohenGreat Neck$27K
- Inna ShifrinBrooklyn$21K
- Amit SaxenaBronx$16K
- Nirmala TummalapentaBronx$16K
- Nasem SayeghElmsford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.